Raaj Medisafe India Limited delivered impressive financial performance in Q3FY26, demonstrating strong operational efficiency and market demand across its business segments. The company's latest quarterly results highlight significant growth momentum in both revenue generation and profitability metrics.

Financial Performance Overview

The company's financial results for Q3FY26 showcase substantial improvement across key performance indicators:

Segment-wise Performance Analysis

The company operates through two primary business segments, both contributing to the overall growth:

Plastic Segment

The plastic segment generated revenue of ₹1,423.44 lakhs during Q3FY26, with segment results of ₹313.18 lakhs. For the nine-month period, this segment achieved revenue of ₹3,459.07 lakhs with results of ₹520.74 lakhs.

Hygiene Segment

The hygiene segment contributed ₹653.23 lakhs in revenue for Q3FY26, with segment results of ₹42.98 lakhs. The nine-month performance showed revenue of ₹2,066.75 lakhs and results of ₹426.63 lakhs.

Nine-Month Performance Highlights

The company's cumulative performance for the nine months ended December 31, 2025, demonstrates sustained growth:

Cost Management and Operational Efficiency

The company demonstrated effective cost management during the quarter. Cost of material consumed increased to ₹1,571.85 lakhs from ₹919.08 lakhs in Q3FY25, primarily due to higher production volumes. Employee benefits expense rose marginally to ₹147.43 lakhs from ₹139.61 lakhs, while finance costs increased to ₹138.29 lakhs from ₹51.61 lakhs, reflecting business expansion activities.

Balance Sheet Strength

As of December 31, 2025, the company maintained a robust balance sheet with total assets of ₹9,627.90 lakhs. The paid-up equity share capital stood at ₹1,314.93 lakhs with a face value of ₹10 per share. Reserves excluding revaluation reserves increased significantly to ₹1,737.80 lakhs compared to negative ₹6.69 lakhs in the previous year.

Corporate Governance and Compliance

The financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on February 11, 2026. The statutory auditors GDK & Associates conducted a limited review of the results and provided an unqualified review report, confirming compliance with applicable accounting standards and regulatory requirements under SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Raaj medisafe India Limited has announced that its Board of Directors will convene on February 11, 2026, at 3:00 PM to deliberate on the company's third quarter financial performance and other statutory matters. The meeting will take place at the company's registered office located at 75/2 & 3, Industrial Area, Maksi Road, Ujjain-456010.

Key Agenda Items

The board meeting will address several critical business matters for the quarter ended December 31, 2025:

Regulatory Compliance Matters

The board will take on record several quarterly compliance reports submitted to BSE:

• Statement of investor complaints
• Shareholding pattern report
• Integrated governance report
• Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018

Meeting Structure

The meeting agenda includes provisions for additional items to be considered with the Chairman's permission and majority director consent, including at least one Independent Director if present. The company has notified BSE Limited about this scheduled meeting in compliance with regulatory requirements.

Company Information

Raaj Medisafe India Limited, with scrip code 524502 on BSE, operates from its registered office in Ujjain's industrial area. The meeting notice was signed by Chairman and Managing Director Arpit Bangur (DIN: 02600716) on February 2, 2026.